What are the first‑line mood‑stabilizer medications, dosing, and monitoring recommendations for an adult with bipolar disorder?

First-Line Mood Stabilizers for Adult Bipolar Disorder

For adults with bipolar disorder, lithium, valproate, and lamotrigine are the established first-line mood stabilizers, with lithium being the gold standard for maintenance therapy and suicide prevention, while atypical antipsychotics (quetiapine, aripiprazole, olanzapine) serve as equally valid first-line options depending on the phase of illness. 1, 2, 3

Treatment Selection by Phase of Illness

The choice of first-line agent depends critically on which phase you're treating:

Acute Mania

• Lithium or valproate are traditional first-line choices
• Atypical antipsychotics (aripiprazole, quetiapine, olanzapine, risperidone, asenapine) are equally first-line and often preferred when rapid control is needed 1, 2
• Combination therapy (mood stabilizer + antipsychotic) is frequently required and appropriate from the start

Bipolar Depression

• Quetiapine (monotherapy or adjunctive) is the most robustly supported first-line option 2
• Lamotrigine is first-line but evidence for acute monotherapy is weak; works better for maintenance 2, 3
• Lithium is recommended first-line though acute efficacy data are less clear 2
• Olanzapine-fluoxetine combination is first-line for acute bipolar depression 2
• Avoid antidepressant monotherapy—it destabilizes the illness and may trigger mania 4

Maintenance/Prophylaxis

• Lithium remains the gold standard with unique anti-suicide properties 5, 2, 3
• Lamotrigine is first-line, particularly for preventing depressive recurrence 2, 3
• Valproate, olanzapine, quetiapine, and aripiprazole are all first-line maintenance options 2, 3

Dosing and Monitoring

Lithium

Dosing:

• Target plasma level: 0.6-0.8 mmol/L for maintenance (consensus across guidelines) 5
• Acute mania may require higher levels (0.8-1.2 mmol/L)
• Elderly patients: start with lower targets initially 5

Monitoring:

• Baseline: renal function (creatinine, eGFR), thyroid function (TSH, free T4), pregnancy test, ECG if indicated
• Lithium level: check 5-7 days after initiation or dose change (12 hours post-dose)
• Ongoing: lithium level every 3-6 months; renal and thyroid function every 6-12 months 5
• Watch for polyuria, tremor, weight gain, cognitive dulling

Valproate/Divalproex

Dosing:

• Start 500-750 mg/day divided doses
• Target: 50-125 μg/mL serum level
• Typical dose: 1000-2000 mg/day

Monitoring:

• Baseline: liver function tests, CBC, pregnancy test (teratogenic—avoid in women of childbearing potential)
• Ongoing: LFTs and CBC at 1-2 months, then periodically
• Watch for weight gain, tremor, hair loss, thrombocytopenia, hepatotoxicity

Lamotrigine

Dosing (critical to prevent Stevens-Johnson syndrome):

• Weeks 1-2: 25 mg daily
• Weeks 3-4: 50 mg daily
• Week 5: 100 mg daily
• Week 6+: 200 mg daily (target dose)
• Slower titration required if on valproate (increases lamotrigine levels)
• Faster titration possible if on carbamazepine (decreases lamotrigine levels)

Monitoring:

• Watch for rash (stop immediately if develops)
• No routine blood level monitoring required
• Educate patient about rash risk during titration

Quetiapine

Dosing:

• Acute depression: 300 mg/day (can start 50 mg day 1,100 mg day 2,200 mg day 3,300 mg day 4)
• Acute mania: 400-800 mg/day
• Maintenance: 300-800 mg/day

Monitoring:

• Baseline: weight, BMI, waist circumference, fasting glucose, lipid panel
• Ongoing: weight at each visit; metabolic parameters at 3 months, then annually
• Watch for sedation, weight gain, metabolic syndrome, orthostatic hypotension

Critical Clinical Considerations

Avoid these pitfalls:

• Don't use antidepressants as monotherapy—they increase intracellular sodium and destabilize bipolar disorder 4
• Don't use gabapentin or topiramate—controlled studies show they don't work 6
• Don't abruptly discontinue lithium—associated with high relapse rates and increased suicide risk
• Don't forget that valproate is highly teratogenic—use reliable contraception in women of childbearing age

Special populations:

• Rapid cycling: lithium or valproate preferred; avoid antidepressants
• Psychotic features: combination therapy with antipsychotic from the start
• Suicide risk: lithium has unique anti-suicide properties beyond mood stabilization 5, 1
• Pregnancy: lamotrigine has the best safety profile; avoid valproate entirely

Combination therapy is often necessary from the outset, particularly for acute mania with psychotic features or when monotherapy fails. The evidence supports lithium or valproate combined with an atypical antipsychotic 7. Avoid unnecessary polypharmacy, but recognize that bipolar disorder frequently requires multiple agents for adequate control.